This podium explores the importance of better considering adherence to treatment across several diseases. It explores the impact of adherence to lenalidomide oral maintenance therapy on patients' quality of life in Multiple Myeloma, how non-adherence among individuals can be related to their level of depression, to what extend patients with Parkinson disease can face treatment discontinuation, and how "truthful" self-reported adherence contributes to explain heterogeneity in treatment preferences.